Active, not recruitingPHASE1, PHASE2NCT03573700

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
St. Jude Children's Research Hospital
Principal Investigator
Aimee C. Talleur, MD
St. Jude Children's Research Hospital
Intervention
Cyclophosphamide(drug)
Enrollment
24 enrolled
Eligibility
21 years · All sexes
Timeline
20182026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03573700 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials